BioCryst Pharmaceuticals, Inc., a prominent player in the biotechnology sector, operates within the Health Care industry and is headquartered in Durham, United States. The company is dedicated to discovering novel, oral, small-molecule medicines aimed at treating rare diseases where enzymes play a crucial role in the biological pathways of these conditions. By addressing significant unmet medical needs, BioCryst Pharmaceuticals extends its services to clients worldwide.
As of July 30, 2026, BioCryst Pharmaceuticals’ stock closed at $8.98 on the Nasdaq exchange, where it is publicly traded. The company’s market capitalization stands at approximately $2.28 billion USD. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of $11.22 on July 8, 2026, and a low of $6 on October 13, 2025. The company’s price-to-earnings ratio is currently -5.36, reflecting its financial performance and market valuation.
BioCryst Pharmaceuticals was established with its initial public offering on March 3, 1994. The company’s mission is centered around the development of innovative treatments for rare diseases, leveraging its expertise in biotechnology to fulfill critical medical needs globally. For more detailed information about their work and offerings, interested parties can visit their official website at www.biocryst.com .
In a related development within the pharmaceutical industry, Glenmark Pharmaceuticals reported a robust first-quarter performance for FY 2027. The company’s consolidated revenue saw a significant increase of over 23 percent year-on-year, driven by growth across all regions. Notably, North America experienced a strong 41 percent increase, while consumer-care sales in India rose by 28 percent. Glenmark’s formulation business in India continued to outperform its market peers, and its respiratory and dermatology portfolios expanded through new product launches, including a triple-therapy nebulizer and the dermatology agent JABRYUS® in partnership with Pfizer.
In North America, Glenmark added nine new prescription and over-the-counter products and secured additional generic respiratory approvals, reinforcing its market share gains. The company also highlighted ongoing progress in its oncology pipeline through its IGI subsidiary, noting successful clinical milestones for multispecific antibody candidates and continued regulatory activity for partner-licensed therapies. Glenmark’s strategy of strengthening core businesses while advancing differentiated specialty platforms appears to be generating sustainable growth and market traction.
